Premium
Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib
Author(s) -
Zhou Amy,
Kong Tim,
Fowles Jared S.,
Jung ChunLing,
Allen Maggie J.,
Fisher Daniel A. C.,
Fulbright Mary,
Nemeth Elizabeta,
Ganz Tomas,
Oh Stephen T.
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18044
Subject(s) - ruxolitinib , myelofibrosis , hematology , medicine , hepcidin , anemia , bone marrow